<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03327467</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00083888</org_study_id>
    <nct_id>NCT03327467</nct_id>
  </id_info>
  <brief_title>Expanded Access Protocol: Umbilical Cord Blood Infusions for Children With Brain Injuries</brief_title>
  <official_title>Expanded Access Protocol: Umbilical Cord Blood Infusions for Children With Brain Injuries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joanne Kurtzberg, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <brief_summary>
    <textblock>
      The objective of the study is to enable access to sibling or autologous umbilical cord blood&#xD;
      (UCB) infusions for children with various brain disorders.&#xD;
&#xD;
      The use of UCB in this fashion is based on safety and efficacy data from prior and ongoing&#xD;
      clinical trials at Duke University Medical Center in over 700 patients with these diagnoses&#xD;
      infused with autologous or sibling UCB over the past decade.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this protocol is to enable access to sibling or autologous umbilical&#xD;
      cord blood for children with various brain disorders. Children with autism, apraxia, cerebral&#xD;
      palsy, hydrocephalus, hypoxic brain injury, stroke, and other brain injuries will be eligible&#xD;
      if they do not qualify for or are unable to participate in another active clinical trial at&#xD;
      Duke. Children with qualifying partially or fully matched sibling or autologous cord blood&#xD;
      units will be eligible. The family will be enrolled on the screening protocol, &quot;A Research&#xD;
      Database and Screening Protocol for Children with Brain Injuries Potentially Undergoing&#xD;
      Cellular Therapy or Other Clinical Trials,&quot; Pro00063563. Information may be obtained under&#xD;
      this protocol including but not limited to: diagnostic information, genetic testing, videos&#xD;
      and pictures of the child, cord blood report, etc. The PI or her designee will review this&#xD;
      information to determine if the child might be eligible for a cord blood infusion(s) on this&#xD;
      expanded access protocol.&#xD;
&#xD;
      If eligible, the child must come to Duke with a parent or legal guardian for clinical&#xD;
      evaluations and infusion of the umbilical cord blood unit. Parents will be required to&#xD;
      participate in remote follow-up phone calls and be willing to complete questionnaires for&#xD;
      safety follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Autism Spectrum Disorder</condition>
  <condition>Autism</condition>
  <condition>Cerebral Palsy</condition>
  <condition>Hydrocephalus</condition>
  <condition>Apraxia of Speech</condition>
  <condition>Hypoxia Ischemia, Cerebral</condition>
  <condition>Drowning; Anoxia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cord Blood Infusion</intervention_name>
    <description>IV infusion of umbilical cord infusion (sibling or autologous)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have a qualifying sibling or autologous cord blood unit&#xD;
&#xD;
          2. Be &lt; 26 years of age at the time of consent.&#xD;
&#xD;
          3. Have given written informed consent according to FDA guidelines (or consent of&#xD;
             parent/legal guardian as applicable).&#xD;
&#xD;
          4. Have baseline blood counts and basic chemistries within normal for age.&#xD;
&#xD;
          5. Have a normal absolute lymphocyte count (ALC) for age on baseline blood count and&#xD;
             differential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Documented HIV or Hepatitis or other disease transmittable through the blood.&#xD;
&#xD;
          2. A cord blood unit that fails to meet specifications&#xD;
&#xD;
          3. Refusal of consent&#xD;
&#xD;
          4. Uncontrolled seizure disorder&#xD;
&#xD;
          5. Uncontrolled infection&#xD;
&#xD;
          6. Diagnosed with a genetic or metabolic disorder related to the neurologic condition&#xD;
&#xD;
          7. History of an immune deficiency&#xD;
&#xD;
          8. History of treatment with chemo or immunosuppressive therapy&#xD;
&#xD;
          9. History of previous allogeneic cell therapy. If previously enrolled on another Duke&#xD;
             cell therapy protocol the subject can still be considered for enrollment on this study&#xD;
&#xD;
         10. Need for mechanical ventilation or chronic O2 support&#xD;
&#xD;
         11. History of inability to protect the airway&#xD;
&#xD;
         12. Eligibility for an active clinical trial of cellular therapies at Duke&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>26 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Joanne Kurtzberg</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jessica Sun</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lettie Moore</last_name>
    <phone>9196681102</phone>
    <email>cordbloodtherapyinfo@dm.duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jayne Cash</last_name>
    <email>cordbloodtherapyinfo@dm.duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Lettie Moore</last_name>
      <email>cordbloodtherapyinfo@dm.duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jayne Cash</last_name>
      <email>cordbloodtherapyinfo@dm.duke.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Silvia Saenz</last_name>
      <email>PediatricCellTherapy@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Kris Mahadeo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 25, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Joanne Kurtzberg, MD</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Cerebral Palsy</mesh_term>
    <mesh_term>Hydrocephalus</mesh_term>
    <mesh_term>Apraxias</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Drowning</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

